WHAT’S IN THIS WEEK’S ISSUE

      • T1D at the Dinner Table: Can We PLEASE Just Enjoy Our Meal?!
      • Tandem Mobi Recall: False Occlusion Alarm, Interrupted Insulin Delivery
      • One Gastroenterologist Approaches Fatty Liver Disease
      • FDA Requires GLP-1 Drugmakers to Warn of Rare Vision Loss
      • Early Pancreatic Biomarker Changes in Children at Risk of T1D
      • Kaleido Patch Pump System Shows Promising Glucose Outcomes
      • Glucose and Ketones: A New Approach to Hypoglycemia Recovery
      • Understanding Inflammation and Metabolic Health
      • Can a 100-Year-Old Vaccine Help Treat T1D? Dr. Denise Faustman
      • The Future of Beta Cell Replacement
      • Dexcom and Libre CGMs: Same Arm, Different GMI
      • Free Monthly Diabetes Technology Newsletter
      • Speaking Up in Every Room: Saira Khan-Gallo
      • Diabetes: Sentenced to a Lifetime of Discipline

NEWS FROM T1DTO100

      • Living Legends: Julian (Yudi) Rubin, 91 Years Old, 81 Years With T1D
      • How to Support Veterans Living With Diabetes


T1Dto100 Webinar: T1D at the Dinner Table — Can We PLEASE Just Enjoy Our Meal?!, Wednesday, 18 November 2026
        • “Should you be eating that?”
        • “Did you take your insulin?”
        • “What’s your blood sugar?”

Sound familiar?!  For those of us living with T1D, mealtimes can sometimes feel like we’re under a microscope.  And for the people who love us, knowing when to help — and when to BACK OFF — isn’t always easy!  With the holidays approaching, let’s talk about making mealtimes happier, less stressful and more enjoyable for EVERYONE at the table.

Join Dana Roseman, MPH, CDCES, RDN, LDN, and Jenny Smith, CDCES, RDN, LDN, two experienced dietitians and diabetes educators, for a practical, honest conversation about supporting T1D at mealtimes.  We’ll discuss food planning, insulin timing, communication and how to offer support without the food police, frustration, guilt or unwanted advice.

AND HERE’S THE BIG ASK: Bring someone who shares meals with you!  Your spouse, partner, adult kids, friends or caregivers — anyone who loves you and wants to help but may not always know HOW.

Because good intentions are wonderful … but understanding each other is even better!
        • WHEN: Wednesday, 18 November 2026
        • TIME: 5 PM PT | 6 PM MT | 7 PM CT | 8 PM ET
        • COST: FREE on Zoom.
        • The webinar will be recorded and shared on our T1Dto100 website and YouTube channel.
        • T1DTO100 NOTE: I hope you’ll join us — and bring someone important in your life. This isn’t just about food or insulin. It’s about relationships, understanding each other and enjoying the simple pleasure of sharing a meal.

REGISTER HERE: https://zoom.us/meeting/register/Vb2Ntf_XSnSTQN4GiBGufw


Tandem Mobi Recall: How to Deal With False Alarms, FDA (https://www.fda.gov) and MedTech Dive (https://www.medtechdive.com), November 2026

Certain Tandem Mobi insulin pumps have been recalled because false occlusion alarms can interrupt insulin delivery even when no blockage is present.  When an occlusion alarm occurs, the pump suspends insulin delivery until the user acknowledges the alarm and resumes therapy. Interrupted delivery can result in dangerously high glucose levels.  Tandem has reported 230 adverse events requiring medical intervention or hospitalization associated with the problem.

The article also examines an important limitation of insulin pump technology: occlusion detection depends on changes in fluid pressure, and not all delivery problems create detectable pressure changes.  At very low basal delivery rates, detecting a true blockage can take several hours or longer. Kinked cannulas, inflamed infusion sites and disconnected tubing may also cause insulin delivery problems without producing an occlusion alarm.

WHAT USERS SHOULD KNOW: The FDA recall instructions advise Mobi users to respond to every occlusion alarm, enable app push notifications and contact Tandem if alarms persist or repeatedly interrupt insulin delivery.  Anyone using an insulin pump should also have a backup insulin-delivery plan developed with their diabetes care team.

Tandem support: 1-877-801-6901

SAVVY NOTE: This is critically important! We depend on these devices to deliver a medication that keeps us alive. An alarm that unnecessarily interrupts insulin is a serious problem — and so is a genuine delivery failure that produces no alarm. Please check whether your pump is affected, pay attention to alerts and have your backup insulin plan ready.

READ MORE: Tandem Mobi Recall: How to Deal With False Alarms

FDA RECALL DATABASE: accessdata.fda.gov/Medical Device Recalls


How One Gastroenterologist Approaches MASLD, published by Managed Healthcare Executive (https://www.managedhealthcareexecutive.com), November 2026

Dr. David Feldshon, a gastroenterologist at Yale New Haven Medical Center, discusses his approach to treating metabolic dysfunction-associated steatotic liver disease (MASLD).  Rather than focusing only on medical recommendations, Feldshon uses motivational interviewing to understand the barriers patients face and help them identify changes they feel ready to make.  His approach emphasizes patience, persistence and individualized care.

Weight management and physical activity remain important components of MASLD treatment. Feldshon also discusses the potential roles of GLP-1 receptor agonists and surgical interventions for selected patients.

WHY IT MATTERS: MASLD is a complex metabolic condition. Successful treatment often depends not only on identifying effective interventions but also on understanding what patients can realistically sustain.

SAVVY NOTE: I particularly appreciate the emphasis on listening to patients! We know that being told what to do isn’t the same as being supported in actually doing it. Understanding each person’s circumstances, barriers and priorities is essential to effective long-term care.

READ MORE: How One Gastroenterologist Approaches MASLD


FDA Tells GLP-1 Makers to Warn of Potential Vision Loss Side Effect, by Daniel Wu for The Washington Post (https://www.washingtonpost.com), 9 November 2026

The FDA announced that manufacturers of GLP-1 medications must add warnings about a potential risk of a rare condition that can cause vision loss.  The condition, non-arteritic anterior ischemic optic neuropathy (NAION), occurs when insufficient blood flow damages the optic nerve, potentially resulting in sudden vision loss in one eye. The warning applies to GLP-1 medications, including drugs such as Ozempic and Wegovy.  NAION is also associated with other risk factors, including diabetes, smoking and high blood pressure. There is currently no established treatment that reliably reverses the resulting vision loss.

However, the available research has limitations.  Dr. Manjot Gill, an ophthalmology professor at Northwestern University, explained that although some studies have identified an association between GLP-1 use and NAION, the evidence remains inconclusive and the absolute risk is very low — estimated in the article at approximately six cases per 100,000 patients.

THE IMPORTANT CONCLUSION: The FDA warning identifies a potential safety concern, but the evidence does not establish that GLP-1 medications cause every reported case of NAION. Patients and clinicians must consider the potential risk alongside the medications’ established benefits.

SAVVY NOTE: This is important information, particularly as GLP-1 medications are being used by more people, including some with T1D. The absolute risk appears very small, but vision loss is serious. Anyone experiencing sudden changes in vision should seek urgent medical evaluation. Please discuss medication concerns with your physician rather than stopping treatment on your own.

READ MORE: FDA Tells GLP-1 Makers to Warn of Potential Vision Loss Side Effect

ADDITIONAL: FDA adds rare vision-loss warning to popular GLP-1 drugs


Early Exocrine Pancreatic Biomarker Changes in Children at Risk of Type 1 Diabetes, by MedXY Editorial Team for MedXY (https://www.medxy.ai), 9 November 2026

 

 

 

Researchers analyzing data from the longitudinal ENDIA study identified early changes in two biomarkers associated with the exocrine pancreas — the part of the pancreas responsible for producing digestive enzymes.  The biomarkers were:

        • Fecal elastase-1 (FE-1), measured in stool.
        • Immunoreactive trypsin (IRT), measured in blood.

FE-1 levels were lower during the first six months of life among children who subsequently developed multiple islet autoantibodies or T1D.  IRT levels declined in the months preceding a T1D diagnosis.  These findings suggest that changes in exocrine pancreatic function may occur before clinical T1D develops.

THE CONCLUSION: The researchers propose that exocrine pancreatic biomarkers could eventually contribute to identifying children at increased risk of T1D and improving our understanding of the disease’s early development.  Further research is needed before these tests could be used as established tools for predicting T1D in clinical practice.

SAVVY NOTE: Fascinating! We generally think of T1D in terms of insulin-producing beta cells, but the pancreas has other important functions. Understanding what happens in the exocrine pancreas before diagnosis may provide new clues about how T1D develops.

READ MORE: Exocrine Pancreatic Biomarker Changes in Children at Risk of T1D


A New Insulin Patch Pump System Could Reduce Hypoglycaemia, by Diabetes Research & Wellness Foundation (https://www.drwf.org.uk), 10 November 2026

European medical device company ViCentra has reported encouraging real-world results involving 3,918 adults with type 1 diabetes using its Kaleido insulin patch pump.  The system combines the Kaleido pump, Diabeloop’s DBLG1 automated insulin delivery algorithm and the Dexcom G6 continuous glucose monitor.  Results presented at the 2026 European Association for the Study of Diabetes meeting in Milan indicated that users achieved recommended international time-in-range targets while experiencing low glycemic variability and minimal hypoglycemia.  Lead study author Dr. Fred Storms emphasized that the findings provide information about how the system performs outside the controlled environment of a clinical trial.

THE CONCLUSION: These observational results suggest that the Kaleido/DBLG1 system can provide stable glucose outcomes in routine use. However, the report does not establish that it is superior to other automated insulin delivery systems.

SAVVY NOTE: More pump choices and better real-world data are welcome! I especially appreciate research looking at hypoglycemia and glucose variability, not simply average glucose or A1C. Reliability and the everyday experience of using a system matter enormously.

READ MORE: A New Insulin Patch Pump System Could Reduce Hypoglycaemia


Glucose Drink With Ketone Substrate Eases Hypoglycemia Recovery in Type 1 Diabetes Trial, published by Bioengineer.org (https://bioengineer.org), 6 November 2026

A randomized, open-label crossover study investigated whether combining glucose with beta-hydroxybutyrate, a ketone body, could improve the experience of recovering from hypoglycemia.  Adults with T1D compared a recovery drink known as FLO23011 with conventional glucose gel.  Participants rated the experimental drink more favorably in 13 of 14 patient-reported domains.  Interviews identified three recurring themes. The study was published in Diabetes Therapy.

        • Faster perceived recovery of cognitive function.
        • Less disruption to everyday activities.
        • Greater confidence in managing hypoglycemia.

THE IMPORTANT DISTINCTION: These findings concern patients’ reported recovery experiences. They do not, by themselves, establish that the drink corrects low blood glucose faster, prevents severe hypoglycemia or improves objectively measured cognitive recovery.

SAVVY NOTE: We all know that recovering from a low is about more than getting the glucose number back into range. The mental fog, fatigue and interruption to our day can linger. I’m interested in research that considers how people actually feel during recovery, but we need more evidence before changing established hypoglycemia treatment practices.

READ MORE: Glucose Drink With Ketone Substrate Eases Hypoglycemia Recovery in T1D Trial


What to Know About Inflammation and Metabolic Health, by Andrew Saintsing for diaTribe (https://diatribe.org), 9 November 2026

Inflammation is an essential part of the body’s immune response, helping protect against infections and repair injured tissues. But inflammation can become harmful when immune activity persists unnecessarily or continues at low levels over long periods. Chronic low-grade inflammation is associated with several metabolic conditions, including those grouped under cardiovascular-kidney-metabolic (CKM) syndrome. Unlike acute inflammation, which may cause noticeable swelling, heat or pain, chronic low-grade inflammation often produces no obvious symptoms.  The article explores the difference between beneficial and harmful inflammation and examines what research tells us about reducing chronic inflammatory activity.

WHAT THE EVIDENCE SUGGESTS: Broad lifestyle patterns, including Mediterranean-style eating, regular physical activity, sufficient sleep and stress management, may help reduce inflammatory markers such as C-reactive protein (CRP).  However, individual foods and supplements promoted for their anti-inflammatory properties frequently fail to demonstrate meaningful benefits in controlled clinical studies.

SAVVY NOTE: Inflammation has become such a popular topic, and there are endless claims about special foods and supplements. I appreciate the distinction between sound research and marketing promises. Our bodies need inflammation to heal — the challenge is understanding when it becomes harmful and what actually helps.

READ MORE: What to Know About Inflammation and Metabolic Health


Can a 100-Year-Old Vaccine Impact Type 1 Diabetes? A Conversation With Dr. Denise Faustman, hosted by Stacey Simms for Diabetes Connections (https://diabetes-connections.com), 10 November 2026

Stacey Simms interviews Dr. Denise Faustman about her ongoing research into the BCG vaccine as a possible treatment for people living with type 1 diabetes.  BCG has been used for many decades as a vaccine against tuberculosis, but Faustman’s research explores whether it may also influence immune and metabolic pathways relevant to T1D.  In the interview, Faustman discusses findings from her clinical research, including reported changes in A1C, insulin use and time in range.  Simms also directly addresses the controversy surrounding the research.

Faustman’s work has generated significant scientific debate, including questions about study design, interpretation of results and whether reported benefits can be reproduced independently.

THE IMPORTANT CONCLUSION: BCG is not an established treatment or cure for type 1 diabetes. Larger, independently validated clinical trials are necessary before claims of meaningful clinical benefit can be accepted.

SAVVY NOTE: I’ve followed Dr. Faustman’s work for many years. This is an important interview because Stacey doesn’t shy away from the scientific controversy. We need creative research and new ideas — but we also need rigorous evidence, transparency and independent confirmation. I encourage you to listen and form your own informed opinion.


Shift in Focus: From Management of Symptoms to Disease-Modifying Therapies and Functional Cures, by Carolyn Robertson for Strong on Insulin Group, New York Diabetes Program (https://newyorkdiabetesprogram.com), November 2026

Carolyn Robertson discusses an important shift in type 1 diabetes research: moving beyond the management of glucose and symptoms toward therapies that could fundamentally change the course of the disease.  Emerging beta cell replacement approaches include:

        • Stem cell-derived insulin-producing beta cells.
        • Gene-edited cell products designed to reduce immune rejection.
        • Islet cells derived from induced pluripotent stem cells (iPSCs).

Early clinical studies suggest that these technologies may eventually expand access to beta cell replacement beyond people experiencing severe hypoglycemia or other particularly difficult complications.  The potential advantages include reducing dependence on deceased organ donors and developing ways to avoid or reduce long-term immunosuppression.

THE IMPORTANT CONCLUSION: The scientific advances justify cautious optimism, but most approaches remain investigational. Long-term cell survival, immune protection, safety, scalability and equitable access are major unresolved challenges.

SAVVY NOTE: This is the direction so many of us have hoped for over decades of living with T1D! We’ve seen extraordinary progress in managing the disease. Now researchers are increasingly exploring ways to restore insulin production itself. I especially hope that older adults with long-duration T1D will not be overlooked as these therapies advance.

READ MORE: From Management of Symptoms to Disease-Modifying Therapies and Functional Cures


The Libre and Dexcom CGMs Shared an Arm. They Didn’t Share a GMI, by Tim Street for Diabettech (https://www.diabettech.com), 11 November 2026

Tim Street describes an intriguing personal experiment wearing a Dexcom G7 and a Libre 2 Plus sensor on the same arm. At one point, his Dexcom displayed approximately 180 mg/dL, while his Libre showed about 140 mg/dL. Both sensors appeared to be following the same glucose trend, but their absolute readings differed considerably. 

During the experiment, Tim replaced the Dexcom G7 five times while continuing to use the same Libre sensor. At four replacement points, the difference between the sensors shifted by approximately 13–46 mg/dL. At the fifth, the change was much smaller. When he replaced the Libre while keeping the same Dexcom, the difference shifted by approximately 26 mg/dL.

These observations raise questions about sensor-to-sensor variation and the reliability of glucose management indicator (GMI) estimates. GMI is calculated from CGM glucose data and is often compared with laboratory A1C. Differences between sensor readings may contribute to discrepancies between GMI estimates and measured A1C.

THE IMPORTANT CONCLUSION: This was one person’s experience, not a controlled clinical study. It cannot establish which sensor was more accurate or how often similar discrepancies occur. But it illustrates why GMI values from different sensors should not automatically be treated as interchangeable.

SAVVY NOTE: This really caught my attention! Many of us have experienced differences between CGM readings and fingersticks, or between GMI and laboratory A1C. Tim’s experiment is a useful reminder that the numbers we rely on are estimates — and that changing sensors may change the numbers even when our underlying glucose patterns haven’t changed much.

READ MORE: The Libre and Dexcom CGMs Shared an Arm. They Didn’t Share a GMI


Free Monthly: Time in Range Coalition (https://www.timeinrange.org), November 2026

The Time in Range Coalition offers a free monthly newsletter designed to help people with diabetes and healthcare professionals better understand diabetes technology and glucose metrics.  Resources include:

 

        • CGM comparison guides.
        • Explanations of time in range and other CGM metrics.
        • Updates on automated insulin delivery systems.
        • Mental health resources.
        • Articles written by people living with diabetes.
        • News and expert advice about emerging technology.

WHY IT MATTERS: As diabetes technology becomes more sophisticated, understanding the information it provides is increasingly important.

SAVVY NOTE: A useful resource for anyone trying to keep up with the ever-changing world of CGMs, AID systems and diabetes data. There’s so much information available — and sometimes it’s nice to have it organized and delivered directly to your inbox!

LEARN MORE AND SUBSCRIBE: Time in Range Coalition


Speaking Up in Every Room, by Neil Israel for Diabetes Made Visible #34, In-Range Animation (https://www.in-range-animation.com), 10 November 2026

Meet Saira Khan-Gallo, whose experience living with type 1 diabetes has shaped a career in education, research and advocacy.  Diagnosed with T1D and diabetic ketoacidosis as a child in Pakistan, Saira has worked in communities with widely varying levels of access to diabetes care. Her experiences include Peace Corps service in the Eastern Caribbean, fieldwork in rural Pakistan and service on the board of a refugee resettlement organization in Southern California. She now works at Tidepool as a principal investigator and senior leader in clinical engagement.

Her personal and professional experiences have made her particularly aware of the enormous disparities in access to diabetes technology, education and healthcare. Saira describes the emotional complexity of having access to care that remains unavailable to many of the communities she has served.

SAVVY NOTE: I love seeing advocates whose work is informed by both lived experience and an understanding of healthcare inequities. Advances in diabetes technology are extraordinary, but access is far from equal. We need more voices like Saira’s helping ensure that progress reaches everyone.

READ MORE: Speaking Up in Every Room


Diabetes — Sentenced to a Lifetime of Discipline, by Derek Brandt for Diabetes Center Berne (https://www.diabetescenterberne.ch), 11 November 2026

Derek Brandt reflects on the relentless responsibility that begins with a diagnosis of type 1 diabetes. From the first insulin injection onward, people living with T1D must make decisions about medication, food, activity and glucose management every day. That responsibility continues during illness, family emergencies, exhaustion and all the other challenges life brings. Unlike many other demands, diabetes management cannot simply be postponed. Brandt explores the emotional weight of having to remain attentive to a condition that never takes a day off.

His central message is that wanting a break from diabetes is entirely human. Better care and better technology should reduce the burden of living with T1D, not simply demand more discipline from the person managing it.

SAVVY NOTE: Oh, does this resonate! After more than six decades with T1D, I understand that relentless responsibility all too well. We can love our lives, appreciate medical progress and still wish for a day when diabetes doesn’t require another thought. We deserve technology, healthcare and support systems that make living with T1D easier — not just more complicated.

READ MORE: Diabetes — Sentenced to a Lifetime of Discipline



NEWS FROM T1DTO100

T1Dto100 Living Legends: Julian (Yudi) Rubin, Age 91, on His 81-Year Journey With T1D, T1Dto100 (https://t1dto100.com), 6 August 2026

What can 81 years of living with type 1 diabetes teach us about health, acceptance, resilience and the challenges of aging?  In the pilot episode of T1Dto100’s Living Legends Project, 91-year-old Julian (Yudi) Rubin shares his extraordinary life with T1D, beginning with his diagnosis in May 1945 at age ten.  At the time, medical expectations for children diagnosed with T1D were dramatically different from today.

Julian recalls being told by physicians at the Joslin Diabetes Center that he would not live past age 30. Instead, he has lived more than eight decades with diabetes and is one of only 19 people to receive Joslin’s 80-Year Lifetime Achievement Award.

In this conversation, Julian reflects on:

        • The role of physical activity and years of demanding work in his life.
        • Learning to accept his diagnosis while continuing to pursue his goals.
        • His relationship with his wife and the challenges they faced together.
        • The importance of individualized diabetes care, especially in healthcare institutions and elder-care settings.

His story offers a remarkable perspective on how much diabetes care has changed — and how much still needs to improve for people growing older with T1D.

T1DTO100 NOTE: THIS is why we created our Living Legends Project!  Julian’s 81-year journey is extraordinary, but what matters just as much is the wisdom and experience he shares about living well, growing older and navigating healthcare systems that don’t always understand long-duration T1D.

We need to hear these voices, preserve their stories and learn from them. I’m so grateful to Julian for sharing his journey with us.

WATCH JULIAN’S INTERVIEW: T1Dto100 Living Legends: Julian (Yudi) Rubin, Age 91, on His 81-Year Journey With T1D

LEARN MORE ABOUT T1DTO100: T1Dto100 Living Legends


How to Support Veterans With Diabetes, by Brittany Mancuso Roper for diaTribe (https://diatribe.org), 9 November 2026

Military veterans may face elevated risks of developing diabetes and may also encounter challenges accessing appropriate care and support.  According to the article, diabetes affects nearly one-quarter of patients receiving care through the U.S. Department of Veterans Affairs, while approximately three million are estimated to have prediabetes.  Contributing factors may include obesity, health disparities, mental health challenges and certain military-related exposures.  Veterans may benefit from resources including:

        • Diabetes self-management education.
        • Individualized nutrition counseling.
        • Specialty diabetes care through VA healthcare services.
        • Peer counseling and support groups.
        • Programs addressing mental health and other conditions that complicate diabetes management.

The article also discusses the role of the Veterans Benefits Administration in helping eligible veterans obtain benefits related to service-connected conditions.

WHY IT MATTERS: Effective diabetes care must account for the physical, emotional and practical challenges veterans may face, including the need for accessible services and ongoing support.

T1DTO100 NOTE: Our veterans deserve comprehensive, compassionate healthcare — including the support needed to manage diabetes as they grow older. I’m glad to see attention being given to the resources available and the importance of making sure people know how to access them.

READ MORE: How to Support Veterans With Diabetes

Share This
Skip to content